Abstract: Objective To evaluate the efficacy and safety of TACE combined with apatinib in the treatment of advanced primary progressive hepatic carcinoma by Meta-analysis. Methods The literatures of randomized controlled studies on TACE combined with apatinib in the treatment of advanced liver cancer from January 1,2015 to July 25,2021 were retrieved for Meta-analysis.Results A total of 20 publications were included,all RCTs,with a total of 1373 patients,including the experimental group (n=687) and the control group (n=686).The objective sustained release rate (ORR) of the experimental group was significantly higher than that of the control group (P<0.05).There was no significant difference in the 6 month survival rate between the two groups (P>0.05),but compared with the control group,the 1 year and 2  year survival ratein the experimental group were significantly higher than those in the control group (P<0.05).There was no significant difference in the incidence of nausea and vomiting between the two groups (P>0.05).The symptoms of fever,abdominal pain,myelosuppression,diarrhea,hypertension,proteinuria,and hand-foot syndrome between groups had statistical significance(P<0.05).Conclusion TACE combined with apatinib is more effective in treating of advanced primary hepatic carcinoma,while the prevention and treatment of adverse effects such as proteinuria,hypertension,and hand-foot syndrome should also be considered.

Key words: apatinib, transcatheter arterial chemoembolization, meta-analysis, hepatic carcinoma